Inovio Pharmaceuticals (NASDAQ:INO) has been granted
$6.9M funding from the Coalition for Epidemic Preparedness Innovations
(CEPI) to work with The International Vaccine Institute (IVI) and the
Korea National Institute of Health for a Phase 1/2 clinical trial of
Inovio’s COVID-19 vaccine candidate (INO-4800) in South Korea.
The company’s DNA vaccine platform was one of the
first technologies to receive support from CEPI to accelerate a COVID-19
vaccine.
Korea had previously announced that it will adopt a
fast-track approval process for COVID-19 vaccine and treatment clinical
trials.
https://seekingalpha.com/news/3561197-inovio-up-7-premarket-on-grant-for-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.